SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 31, 2012
(Exact name of registrant as specified in its charter)
525 Market Street, 36th Floor
San Francisco, California 94105
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (415) 543-3470
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On August 31, 2012, Medivation, Inc. and Astellas Pharma Inc. issued a joint press release entitled U.S. FDA Approves XTANDI® (enzalutamide) after Priority Review for Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel. XTANDI is expected to be commercially available in mid-September, and the wholesale acquisition cost has been set at $7,450 for a 30-day supply. The FDAs approval of XTANDI and the EMAs acceptance for review of the European marketing application for XTANDI trigger milestone payments to Medivation of $30 million and $5 million, respectively, under the collaboration agreement between Medivation and Astellas. Medivation is required to share 10% of these milestone payments with UCLA under the terms of its license agreement.
A copy of the joint press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.